Gottlieb's FDA: Specialized Groups Could Create Review Consistency, Speed
Executive Summary
US FDA commissioner nominee might employ modular specialists to work with review divisions on issues related to gene therapies, molecularly-targeted drugs, adaptive clinical trial designs, or other complex issues.